All Stories

  1. Switching patients in the age of long-acting recombinant products?

    Article • Expert Review of Hematology, January 2019, Taylor & Francis

    Professor Alfonso Iorio

  2. Haemophilia clinical care and research needs: Assessing priorities

    Article • Haemophilia, July 2018, Wiley

    Professor Alfonso Iorio

  3. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome

    Article • Journal of Thrombosis and Haemostasis, July 2018, Wiley

    Professor Alfonso Iorio

  4. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH

    Article • Journal of Thrombosis and Haemostasis, June 2018, Wiley

    Massimo Morfini, Professor Alfonso Iorio

  5. Focusing in on use of pharmacokinetic profiles in routine hemophilia care

    Article • Research and Practice in Thrombosis and Haemostasis, May 2018, Wiley

    Professor Alfonso Iorio, Joanna Davis, Dr Ellis J Neufeld

  6. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

    Article • Research and Practice in Thrombosis and Haemostasis, May 2018, Wiley

    Massimo Morfini, Professor Alfonso Iorio, Dr Ellis J Neufeld

  7. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

    Article • Haemophilia, May 2018, Wiley

    Professor Alfonso Iorio

  8. Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes

    Article • Haemophilia, May 2018, Wiley

    Professor Alfonso Iorio

  9. Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population

    Article • Haemophilia, December 2017, Wiley

    Professor Alfonso Iorio, ANTONIO COPPOLA, Dr Giancarlo Castaman

  10. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

    Article • Journal of Thrombosis and Haemostasis, November 2017, Wiley

    Professor Alfonso Iorio

  11. Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH

    Article • Journal of Thrombosis and Haemostasis, August 2017, Wiley

    Professor Alfonso Iorio

  12. Switching to extended half-life products in Canada - preliminary data

    Article • Haemophilia, May 2017, Wiley

    Professor Alfonso Iorio

  13. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta‐analysis

    Article • Journal of Thrombosis and Haemostasis, May 2017, Wiley

    Dr Chatree CHAIADISAKSOPHA, Professor Alfonso Iorio

  14. Population PK tailoring in hemophilia

    Article • International Journal of Pharmacokinetics, May 2017, Future Science

    Professor Alfonso Iorio

  15. Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more

    Article • British Journal of Haematology, April 2017, Wiley

    Professor Alfonso Iorio

  16. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products

    Article • Haemophilia, February 2017, Wiley

    Professor Alfonso Iorio

  17. Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development

    Article • Haemophilia, February 2017, Wiley

    Professor Alfonso Iorio

  18. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series

    Article • Haemophilia, February 2017, Wiley

    Dr Giancarlo Castaman, Professor Alfonso Iorio

  19. Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data

    Article • Haemophilia, December 2016, Wiley

    Professor Alfonso Iorio

  20. Interpreting trial sequential analysis

    Article • Transfusion, November 2016, Wiley

    Professor Alfonso Iorio

  21. Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study

    Article • Journal of Blood Medicine, October 2016, Dove Medical Press

    Dr Eleanor M Pullenayegum, Professor Alfonso Iorio

  22. Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH

    Article • Journal of Thrombosis and Haemostasis, August 2016, Wiley

    Professor Alfonso Iorio

  23. Methodology for the development of the NHF-McMaster Guideline on Care Models for Haemophilia Management

    Article • Haemophilia, June 2016, Wiley

    Professor Alfonso Iorio

  24. Care models in the management of haemophilia: a systematic review

    Article • Haemophilia, June 2016, Wiley

    Professor Alfonso Iorio

  25. NHF-McMaster Guideline on Care Models for Haemophilia Management

    Article • Haemophilia, June 2016, Wiley

    Professor Alfonso Iorio

  26. Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases

    Article • Haemophilia, June 2016, Wiley

    Professor Alfonso Iorio

  27. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors

    Article • Cochrane Database of Systematic Reviews, December 2015, Wiley

    Professor Alfonso Iorio